Skip to main content
. 2014 Jul 31;111(6):1080–1088. doi: 10.1038/bjc.2014.423

Figure 5.

Figure 5

The effects of donor-activating KIR gene on the relapse of recipients with the relevant KIR ligand for the activating KIR gene but not for the inhibitory KIR gene. The cumulative incidence estimate for the probability of molecular (A) and haematologic (B) relapse in CML patients with the relevant KIR ligand (HLA-BW4 or HLA-C2 positive) for the donor-activating KIR gene (KIR2DS1 or KIR3DS1) but not for the donor-inhibitory KIR gene (with missing self between donor and patient) after haploidentical T-cell-replete transplantation.